Oral Ibandronate Therapy in Three Patients with Osteogenesis Imperfecta

Introduction: Treatment with orally administered ibandronate is an effective way to increase bone mineral density (BMD) and reduce fracture rate in post-menopausal women and in men with osteoporosis. There are only very few reports concerning ibandronate therapy in children and adolescents, and in p...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Štěpán Kutílek, Ivana Plášilová, Sylva Skálová, Milan Bayer, Erika Ondrušová
Formato:	article
Lenguaje:	EN
Publicado:	Karolinum Press 2021
Materias:	Medicine R
Acceso en línea:	https://doaj.org/article/da761f76a1dc43e59a780af449ac0dc5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:da761f76a1dc43e59a780af449ac0dc5
record_format	dspace
spelling	oai:doaj.org-article:da761f76a1dc43e59a780af449ac0dc52021-11-22T09:31:02ZOral Ibandronate Therapy in Three Patients with Osteogenesis Imperfecta1805-96941211-428610.14712/18059694.2021.32https://doaj.org/article/da761f76a1dc43e59a780af449ac0dc52021-11-01T00:00:00Zhttps://actamedica.lfhk.cuni.cz/64/3/0187/https://doaj.org/toc/1211-4286https://doaj.org/toc/1805-9694Introduction: Treatment with orally administered ibandronate is an effective way to increase bone mineral density (BMD) and reduce fracture rate in post-menopausal women and in men with osteoporosis. There are only very few reports concerning ibandronate therapy in children and adolescents, and in patients with osteogenesis imperfecta (OI), as bisphosphonates are not registered for therapeutic use in pediatrics. Case Report: We present three patients with OI, where once-monthly oral ibandronate increased spinal BMD after two and four years, respectively, of therapy without any occurrence of new fractures and no adverse reactions. Somatic growth was not affected by the ibandronate treatment. Conclusion: Once-monthly oral ibandronate increased BMD and most probably improved bone quality in young patients with OI.Štěpán KutílekIvana PlášilováSylva SkálováMilan BayerErika OndrušováKarolinum PressarticleMedicineRENActa Medica, Vol 64, Iss 3, Pp 187-192 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R
spellingShingle	Medicine R Štěpán Kutílek Ivana Plášilová Sylva Skálová Milan Bayer Erika Ondrušová Oral Ibandronate Therapy in Three Patients with Osteogenesis Imperfecta
description	Introduction: Treatment with orally administered ibandronate is an effective way to increase bone mineral density (BMD) and reduce fracture rate in post-menopausal women and in men with osteoporosis. There are only very few reports concerning ibandronate therapy in children and adolescents, and in patients with osteogenesis imperfecta (OI), as bisphosphonates are not registered for therapeutic use in pediatrics. Case Report: We present three patients with OI, where once-monthly oral ibandronate increased spinal BMD after two and four years, respectively, of therapy without any occurrence of new fractures and no adverse reactions. Somatic growth was not affected by the ibandronate treatment. Conclusion: Once-monthly oral ibandronate increased BMD and most probably improved bone quality in young patients with OI.
format	article
author	Štěpán Kutílek Ivana Plášilová Sylva Skálová Milan Bayer Erika Ondrušová
author_facet	Štěpán Kutílek Ivana Plášilová Sylva Skálová Milan Bayer Erika Ondrušová
author_sort	Štěpán Kutílek
title	Oral Ibandronate Therapy in Three Patients with Osteogenesis Imperfecta
title_short	Oral Ibandronate Therapy in Three Patients with Osteogenesis Imperfecta
title_full	Oral Ibandronate Therapy in Three Patients with Osteogenesis Imperfecta
title_fullStr	Oral Ibandronate Therapy in Three Patients with Osteogenesis Imperfecta
title_full_unstemmed	Oral Ibandronate Therapy in Three Patients with Osteogenesis Imperfecta
title_sort	oral ibandronate therapy in three patients with osteogenesis imperfecta
publisher	Karolinum Press
publishDate	2021
url	https://doaj.org/article/da761f76a1dc43e59a780af449ac0dc5
work_keys_str_mv	AT stepankutilek oralibandronatetherapyinthreepatientswithosteogenesisimperfecta AT ivanaplasilova oralibandronatetherapyinthreepatientswithosteogenesisimperfecta AT sylvaskalova oralibandronatetherapyinthreepatientswithosteogenesisimperfecta AT milanbayer oralibandronatetherapyinthreepatientswithosteogenesisimperfecta AT erikaondrusova oralibandronatetherapyinthreepatientswithosteogenesisimperfecta
_version_	1718417826017968128

Oral Ibandronate Therapy in Three Patients with Osteogenesis Imperfecta

Ejemplares similares